0PB Stock Chart & Stats
€5.05
-€0.20(-5.62%)
At close: 4:00 PM EST
€5.05
-€0.20(-5.62%)
Day’s Range― - ―
52-Week Range€2.63 - €5.20
Previous CloseN/A
Volume0.00
Average Volume (3M)62.00
Market Cap
€356.62M
Enterprise Value€347.76M
Total Cash (Recent Filing)€101.55M
Total Debt (Recent Filing)€15.95M
Price to Earnings (P/E)16.1
Beta0.68
Next Earnings
Jul 30, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding50,899,456
10 Day Avg. Volume160
30 Day Avg. Volume62
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.28
Price to Sales (P/S)1.30
P/FCF Ratio7.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.37Price Target Upside-13.37% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.21
Revenue Forecast (FY)€184.87M
Bulls Say, Bears Say
Bulls Say
Analyst ConfidencePuma's price target was adjusted upwards from $4.00 to $5.00, suggesting increased confidence in future performance.
EarningsPuma reported Q3 Nerlynx sales of $51.9MM, which was above consensus estimates of $47.5MM.
Financial OutlookThe company raised its FY 2025 revenue and net income guidance slightly, indicating a positive outlook.
Bears Say
Product ConfidenceThere is a lack of confidence in alisertib, and the recommendation remains at Hold.
Revenue ChallengesSignificant accelerations in product and royalty revenue are needed in Q4 to support the full year guidance.
Puma Biotechnology News
0PB FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was €2.63 and its highest was €5.20 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is €356.62M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on May 07, 2026. The company reported -€0.061 earnings per share for the quarter, beating the consensus estimate of -€0.149 by €0.088.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Overvalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is 0.04.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 50,899,456 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of -€0.061 in its last earnings report, beating expectations of -€0.149. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in DE:0PB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.08%
12-Months-Change
Fundamentals
Return on Equity
20.37%
Trailing 12-Months
Asset Growth
-1.77%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
0PB Company Deck
0PB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic view: despite a notable sequential decline in Q1 revenue and a substantial drop in royalties driven by timing and inventory effects, management strengthened full-year revenue and net income guidance, retired debt and maintained a solid cash position. Commercial execution showed improvement in new starts, enrollments and salesforce activity, and the alisertib Phase II interim data revealed promising biomarker-driven signals (c-Myc enrichment, ESR1-mutant/PIK3CA–wild-type subsets) and manageable safety with prophylactic G-CSF in lung trials. Key near-term risks include elevated gross-to-net rates, higher R&D spending, inventory variability affecting quarterly results, and neutropenia at higher doses in breast cohorts. On balance, positives around raised guidance, strong balance-sheet actions, improving commercial metrics, and encouraging clinical signals outweigh the quarter-specific revenue headwinds.View all DE:0PB earnings summaries0PB Stock 12 Month Forecast
Average Price Target
€4.37
▼(-13.37% Downside)
Technical Analysis
Heron Therapeutics
―
Voyager Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Options Prices
Currently, No data available
---